History and Origins

The technology was conceptualized by current CEO in the mid-90’s at the request of an inquirer who became a collaborator/co-inventor. The state of transdermal art was analyzed and key parameters controlling transdermal flux identified and system to modulate these characteristics composed of GRAS-listed substances developed.

​

Intellectual property situation

The Company’s technology is protected by three (3) broad patents in the United States and twenty (20) additional patents issued in the EU, Canada, Mexico and Japan.

​

Organization

The company was founded in 2012 and is located in Southeastern US.

It has 5 FTE and recently engaged investment banking to assist in the capital raise. Management team has long history in pharmaceutical sector.

​

Key Takeaways

The company can provide a safer and faster delivery of drugs combined with a billion-dollar market potential at a low incremental cost.

In addition to providing immediate delivery, it provides a more direct means to deliver a much smaller, but equally effective dose of drugs.

Management has very good understanding of the pharma market and should be able to secure licensing and partnerships.  

​